Clinical Trials
24 trialsNCT04960709 2026-06-04
VOLGA
AstraZeneca
Phase 3 Active not recruiting
NCT07421700 2026-06-04
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Pfizer
Phase 1/2 Recruiting
NCT07484022 2026-06-03
Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
Generate Biomedicines
Phase 1 Recruiting
NCT04223856 2026-05-29
EV-302
Astellas Pharma Inc
Phase 3 Active not recruiting
NCT06862219 2026-05-28
A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer
Astellas Pharma Inc
Phase 4 Recruiting
NCT05614739 2026-05-19
FORAGER-1
Eli Lilly and Company
Phase 1 Recruiting
NCT07475806 2026-05-15
A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
Astellas Pharma Inc
Phase 2 Recruiting
NCT06011954 2026-05-14
A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection
Astellas Pharma Inc
Recruiting
NCT07566156 2026-05-11
EV-309
Astellas Pharma Inc
Phase 3 Recruiting
NCT07232602 2026-04-24
MK-3475-04D
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT07287995 2026-04-23
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Astellas Pharma Inc
Phase 1/2 Recruiting
NCT04225117 2026-04-13
A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
Astellas Pharma Inc
Phase 2 Active not recruiting
NCT03288545 2026-03-24
EV-103
Astellas Pharma Inc
Phase 1/2 Terminated
NCT03547973 2026-03-16
TROPHY U-01
Gilead Sciences
Phase 2 Recruiting
NCT06483334 2026-02-18
MK-3475-04C
Merck Sharp & Dohme LLC
Phase 1/2 Active not recruiting
NCT04700124 2026-02-05
KEYNOTE-B15
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03869190 2026-01-22
Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)
Hoffmann-La Roche
Phase 1/2 Completed
NCT06305767 2026-01-13
INTerpath-005
Merck Sharp & Dohme LLC
Phase 1/2 Active not recruiting
NCT03474107 2026-01-09
A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)
Astellas Pharma Inc
Phase 3 Completed
NCT05014139 2025-11-20
A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)
Astellas Pharma Inc
Phase 1 Terminated
NCT04995419 2025-10-07
A Study to Evaluate Enfortumab Vedotin (ASG-22CE) in Chinese Participants With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Platinum-containing Chemotherapy and Programmed Cell Death Protein-1 ( PD 1) / (Programmed Death Ligand-1 (PD-L1) Inhibitor Therapy
Astellas Pharma Inc
Phase 2 Completed
NCT07157956 2025-09-05
CVL006-T1002
Convalife (Shanghai) Co., Ltd.
Phase 1/2 Not yet recruiting
NCT03924895 2025-08-28
KEYNOTE-905
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT05524545 2025-07-25
A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)
ALX Oncology Inc.
Phase 1 Completed